Negative anti-C1q antibody titers may influence therapeutic decisions and reduce the number of renal biopsies in systemic lupus erythematosus

Nephron - Clinical Practice

Volumn 118, Issue 4, 2011, Pages

  Guerreiro De Moura, Carlos Geraldo ^a,b,c   Pitangueira Mangueira, Cristóvão Luis ^e,f   Sampaio Cruz, Luzia Arlinda ^d   Sampaio Cruz, Constança Margarida ^a,b,g  

^a ESCOLA BAHIANA DE MEDICINA E SAÚDE PÚBLICA   (Brazil)

^b Coordination of the Residency Program in Internal Medicine ^*  (Brazil)

^c Hospital Santo Antonio   (Brazil)

^d Clinic of Kidney and Hypertension   (Brazil)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^g Israel Institute of Education and Research São Paulo ^*  (Brazil)

Author keywords

Anti C1q; Lupus nephritis; Systemic lupus erythematosus; Systemic Lupus Erythematosus Disease Activity Index

Indexed keywords

AUTOANTIBODY; CHLOROQUINE; COMPLEMENT COMPONENT C1Q; CREATININE; CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; PREDNISONE;

ADULT; ANTIBODY TITER; ARTICLE; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEINURIA; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AUTOANTIBODIES; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; COMPLEMENT C1Q; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; YOUNG ADULT;

EID: 79851509167     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000323388     Document Type: Article

References (16)

1. Pickering MC, Botto M: Are anti-C1q antibodies different from other SLE autoantibodies? Nat Rev Rheumatol 2010; 6: 490-493.
2. Ogden CA, deCathelineau A, Hoffmann PR, Bratton D, Ghebrehiwet B, Fadok VA, Henson PM: C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic bodies. J Exp Med 2001; 194: 781-796.
3. Bigler C, Schaller M, Perahud I, Osthoff M, Trendelenburg M: Autoantibodies against complement C1q specifically target C1q bound on early apoptotic cells. J Immunol 2009; 183: 3512-3521.
4. Mannik M, Wener M: Deposition of antibodies to the collagen-like region of C1q in renal glomeruli of patients with proliferative lupus glomerulonephritis. Arthritis Rheum 1997; 40: 1504-1511. (Pubitemid 27430963)
5. Uwatoko S, Gauthier VJ, Mannik M: Autoantibodies to the collagen-like region of C1q deposit in glomeruli via C1q in immune deposits. Clin Immunol Immunopathol 1991; 61: 268-273.
6. Trouw LA, Groeneveld TW, Seelen MA, Duijs JM, Bajema IM, Prins FA et al: Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 2004; 114: 679-688. (Pubitemid 39578758)
7. Trendelenburg M, Lopez-Trascasa M, Potlukova E, Moll S, Regenass S, Frémeaux-Bacchi V, et al: High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant 2006; 21: 3115-3121. (Pubitemid 44567082)
8. Siegert C, Daha MR, Tseng CM, Coremans IE, van Es LA, Breedveld FC: Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Ann Rheum Dis 1993; 52: 851-856. (Pubitemid 24019139)
9. Marto N, Bertolaccini ML, Calabuig E, Hughes GRV, Khamashta MA: Anti-C1q antibodies in nephritis: Correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 444-448. (Pubitemid 40283057)
10. Kravitz MS, Shoenfeld Y: Autoimmunity to protective molecules: Is it the perpetuum mobile (vicious cycle) of autoimmune rheumatic diseases? Nat Clin Pract Rheumatol 2006; 2: 481-490. (Pubitemid 44340424)
11. Gunnarsson I, Ronnelid J, Huang YJ, Rogberg S, Nilsson B, Lundberg I, et al: Association between ongoing anti-C1q antibody production in peripheral blood and proliferative nephritis in patients with active systemic lupus erythematosus. Br J Rheumatol 1997; 36: 32-37.
12. Coremans IE, Sprank PE, Bootsma H, Daha MR, van der Voort EA, Kater L, et al: Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. Am J Kidney Dis 1995; 26: 595-601.
13. Siegert C, Daha M, Westedt Ml, van der Voort E, Breedveld F: IgG autoantibodies against C1q are correlated to nephritis, hypocomplementemia, and dsDNA antibodies in systemic lupus erythematosus. J Rheumatol 1991; 18: 230-234.
14. Haseley LA, Wisnieski JJ, Denburg MR, Michael-Grossman AR, Ginzler EM, Gourley MF et al: Antibodies to C1q in systemic lupus erythematosus: Characteristics and relation to Fc gamma RIIA alleles. Kidney Int 1997; 52: 1375-1380. (Pubitemid 27496068)
15. Gunnarsson I, Sundelin B, Heimburger M, Forslid J, van Vollenhoven R, Lundberg I et al: Repeated renal biopsy in proliferative lupus nephritis -predictive role of serum C1q and albuminuria. J Rheumatol 2002; 29: 693-699. (Pubitemid 34303862)
16. Trendelenburg M, Marfurt J, Gerber I, Tyndall A, Schifferli JA: Lack of occurrence of severe lupus nephritis among anti-C1q autoantibodies-negative patients. Arthritis Rheum 1999; 42: 187-188. (Pubitemid 29042588)